Condyloma is the medical term for genital warts, a common sexually transmitted infection caused by the human papillomavirus (HPV). These growths appear on or around the genitals and anus, ranging from tiny bumps smaller than 5 mm to larger clusters. There are two distinct types: condyloma acuminata, which are the typical genital warts caused by HPV, and condyloma lata, a much rarer condition caused by syphilis. When most people and most doctors say “condyloma,” they mean acuminata.
What Causes Condyloma
HPV types 6 and 11 are responsible for the vast majority of genital warts. These are considered low-risk strains because they don’t cause cancer on their own. However, it’s possible to be infected with multiple HPV strains at once, including higher-risk types like 16 and 18 that are linked to cervical and other cancers.
HPV spreads most commonly during vaginal or anal sex, but it can also pass through close skin-to-skin contact during any sexual activity, including oral sex. A person can transmit the virus even when they have no visible warts or symptoms. The time between exposure and the appearance of warts varies widely, from weeks to months to even years, which makes it difficult to pinpoint when or from whom you got the infection.
What Condyloma Looks and Feels Like
Genital warts can appear as flat, raised, or stalk-like growths on the genital mucosa. Their texture is often described as cauliflower-like or verrucous (rough and bumpy), and they can show up alone or in clusters. Color ranges from skin-toned to darker, and they occasionally bleed on their own.
Common locations include the vaginal opening, labia, penile shaft, foreskin, scrotum, perineum, and the skin around or inside the anus. Warts can also develop internally, on the cervix, inside the vaginal canal, or within the urethra. Their size, shape, and appearance depend on the exact HPV type involved, the location, and individual factors like immune function.
Many people with genital warts have no pain or itching. Others notice mild irritation, especially with larger clusters or warts in areas that experience friction.
Condyloma Acuminata vs. Condyloma Lata
These two conditions look similar enough to confuse even clinicians, but they have completely different causes. Condyloma acuminata are caused by HPV and present as soft, moist, pink-to-gray growths that are often clustered and have a rough, warty surface. Condyloma lata are a sign of secondary syphilis, caused by the bacterium that causes that infection. They appear as flat-topped, smooth, white or gray lesions, typically 1 to 2 cm across, found in warm, moist areas like the groin and perianal region.
The distinction matters because treatment is entirely different. Condyloma lata is now rare, but when it does appear, it signals an active syphilis infection that requires antibiotic treatment. If there’s any doubt, blood testing for syphilis can quickly clarify the diagnosis.
How Condyloma Is Diagnosed
Most genital warts are diagnosed by visual examination alone. A healthcare provider can usually identify the characteristic appearance without lab tests. In cases where the diagnosis is uncertain, or when warts don’t respond to treatment, a small tissue sample (biopsy) may be taken to rule out other conditions. HPV testing of the warts themselves is not routinely done since it doesn’t change how they’re managed.
Treatment Options and Recurrence
Treatment for genital warts focuses on removing visible growths. This doesn’t eliminate the underlying HPV infection, which is why recurrence is common. Overall, recurrence rates range from 25% to 67% depending on the method used.
There are two broad categories of treatment: things you apply at home and procedures done in a clinic. At-home options include prescription creams and solutions that either destroy wart tissue directly or stimulate your immune system to fight the virus. These are applied over several weeks, and recurrence rates vary. One immune-boosting cream has a recurrence rate around 13%, while a plant-based solution ranges from 4% to 33%. A green tea extract ointment has some of the lowest recurrence rates, around 6% to 7%.
In-clinic procedures include freezing (cryotherapy), surgical removal, and chemical application. Freezing is widely used but has one of the higher recurrence rates, between 38% and 73%. Surgical excision recurs in roughly 19% to 29% of cases. Electrosurgery, which uses electrical current to destroy tissue, has a recurrence rate around 18%. Chemical treatments applied by a provider recur in about 26% to 36% of cases.
No single method works best for everyone. The choice often depends on the number, size, and location of warts, along with personal preference. Some people need multiple treatment sessions or a combination of approaches.
Cancer Risk With Genital Warts
HPV types 6 and 11, the strains behind most genital warts, are not themselves cancer-causing. But having genital warts signals HPV exposure, and co-infection with higher-risk strains is possible. A large population-based study in Taiwan found that people diagnosed with genital warts had roughly twice the overall cancer risk compared to the general population. The risk was most pronounced for HPV-related cancers, nearly tenfold higher, particularly anogenital cancers like anal, penile, and cervical malignancies.
In that study, about 4.6% of genital wart patients developed a malignancy, with most cancers appearing within 10 years of the wart diagnosis. Women faced a notably higher risk of pre-cancerous cervical changes, and more than a third of patients who developed anogenital cancers were diagnosed within one year of their genital wart diagnosis, suggesting co-existing infections at the time. This is one reason routine cervical screening remains important for anyone with a history of genital warts.
Prevention Through Vaccination
The HPV vaccine is highly effective at preventing the strains that cause genital warts. The current nine-strain version covers HPV types 6 and 11 (the main wart-causing strains) along with seven cancer-associated types. Vaccination before exposure to HPV provides the strongest protection, which is why it’s recommended in adolescence, but it can still offer benefit for adults who haven’t been previously vaccinated.
There’s also emerging evidence that the vaccine may help people who already have recurrent, treatment-resistant warts. Small studies have reported significant improvement, including complete clearance in some patients, after a standard three-dose vaccine series. In one study, 85% of patients who received the vaccine alongside standard wart treatment had positive outcomes at 12 months, compared to 33% of those who received standard treatment alone. These findings are preliminary but suggest the vaccine may have therapeutic value beyond prevention.